The polycomb group (PcG) proteins are known to be involved in maintaining the silenced state of several developmentally regulated genes. Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, has also been shown to be deregulated in different tumor types and its role, both as a potential primary effector and as a mediator of tumorigenesis, has become a subject of increased interest. We observed that Ezh2 binds to pRb2/ p130, a member of the retinoblastoma family; as such, we were led to consider the possible ability of Ezh2 to modulate cell cycle progression. Both Ezh2 and pRb2/ p130 repress gene expression by recruiting histone deacetylase (HDAC1), which decreases DNA accessibility for activating transcription factors. Additionally, we observed that Ezh2 interacts with the C-terminal region of pRb2/p130, essential for interaction with HDAC1. We show that Ezh2 is able to reverse pRb2/p130-HDAC1-mediated repression of the cyclin A promoter. This indicates a functional role of this complex in regulating cyclin A expression, known to be crucial in mediating cell cycle advancement. We also detected a significant decrease in the retention of HDAC1 activity associated with pRb2/p130 when Ezh2 was overexpressed. Finally, electromobility shift assays (EMSA) demonstrated that overexpression of Ezh2 caused the abrogation of the pRb2/p130-HDAC1 complex on the cyclin A promoter. These data, taken together, suggest that Ezh2 competes with HDAC1 in binding to pRb2/p130, disrupting their occupancy on the cyclin A promoter. In this study, we propose a new mechanism for the functional inactivation of pRb2/p130 that ultimately contributes to cell cycle progression and malignant transformation.
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Introduction
The polycomb (PcG) and trithorax (trxG) groups of proteins act in multimeric complexes and are normally involved in the regulation of homeobox gene expression (Simon, 1995; Pirrotta, 1997a) . PcG proteins are responsible for the repressed and silenced states of homeotic genes, whereas trxG proteins ensure the maintenance of an active state. Both protein groups collaborate in modulating homeotic expression during normal development (Kennison, 1995; Muller, 1995; Gould, 1997; Pirrotta, 1997b Pirrotta, , 1998 Schumacher and Magnuson, 1997) . Two distinct PcG groups have been identified in humans: the Ezh2/Eed complex containing the Ezh2, Eed and YY1 proteins, and the HPC/HPH complex containing the HPC, HPH, RING1 and Bmi-1 proteins (Gunster et al., 1997; Sewalt et al., 1998; Satijn and Otte, 1999a; Bardos et al., 2000) . Besides regulating homeobox gene expression, many reports indicate that PcG and trxG proteins have a crucial role in cell proliferation, and point to the emerging concept that their deregulation can induce malignant transformation. Overexpression of Bmi-1 causes lymphomas in transgenic mice (Jacobs et al., 1999b) and overexpression of Ring1 leads to cellular transformation and metastatic activity in nude mice (Satijn and Otte, 1999b) . Ezh2 has been shown to be upregulated in prostate cancer (Varambally et al., 2002; Rhodes et al., 2003) , breast cancer (Perou et al., 2000; Kleer et al., 2003) , and in cultured human mantle cell lymphoma (Visser et al., 2001) , while an altered Ezh2 expression pattern has been detected in both Hodgkin's disease (Raaphorst et al., 2000) and B-cell non-Hodgkin's lymphomas (van Kemenade et al., 2001) . Furthermore, Ezh2 overexpression causes an increase in cellular proliferation (Sellers and Loda, 2002) and promotes anchorage-independent growth and cell invasion in immortalized human mammary epithelial cells lines (Kleer et al., 2003) , while inhibition of its expression by antisense oligonucleotides (Fukuyama et al., 2000) and small interfering RNA (siRNA) experiments (Varambally et al., 2002) leads to cell cycle arrest. Involvement of Ezh2 in the control of cellular proliferation is further indicated by its interaction with the Vav proto-oncogene, which plays a critical role in hematopoietic signal transduction (Hobert et al., 1996) . However, the molecular mechanisms that link Ezh2 deregulation to malignant transformation have been poorly explored so far. To gain more insight into the mechanisms of Ezh2 function, we posed the question of whether it may interact with proteins of the cell cycle machinery. In the present study, we focus our interest on pRb2/p130, a member of the retinoblastoma (Rb) family, that regulates the G 0 /G 1 checkpoint through unique growth-suppressing pathways (Pipas, 1992; Carbone et al., 1997; De Luca et al., 1997a; Pupa et al., 1999; Claudio et al., 2002a) . Like pRb/p105 and p107, which are the other two members of the Rb family, pRb2/p130 acts as a transcriptional repressor of cell cycle-promoting genes. The three Rb proteins are known as 'pocket proteins' since they share a high homology bipartite region that constitutes the 'pocket domain'. The pocket domain, characterized by A and B subdomains separated by a spacer region, and the Cterminal region, are important for protein-protein interactions and for the growth-suppressive function of the Rb family members. pRb2/p130 is mainly expressed and active in differentiated and arrested cells in the G 0 / G 1 phase of the cell cycle. Genetic and functional inactivation of pRb2/p130 allow cells to bypass the G 0 / G 1 checkpoint, enabling them to undergo mitosis (Lee et al., 1987; Ewen et al., 1991; Mayol et al., 1993; Claudio et al., 2002a; Tonini et al., 2002 Tonini et al., , 2003 . pRb2/ p130 acts by repressing transcription via binding to E2F4 and E2F5 members of E2F transcription factors (La Thangue, 1996; Sidle et al., 1996; Macaluso et al., 2003; Sanseverino et al., 2003) , which have binding sites for promoters of genes important for progression of cells from G1 to S phase. Recent investigations have shown that the repression of E2F activity by the Rb family members is mediated by the recruitment of histone deacetylase (HDAC1) activity to E2F-containing promoters (Ferreira et al., 1998; Magnaghi-Jaulin et al., 1998; Stiegler et al., 1998) . Histone acetyl transferase (HAT) and HDAC, respectively acetylate or deacetylate the tails protruding from core histones (Turner, 1991) , thus modulating chromatin accessibility for transcription factors. When the binding of the Rb proteins to histone deacetylase is disrupted, the cells are induced to progress through the commitment point. This suggests the importance of HDAC1 for the suppression of cellular proliferation mediated by the pocket proteins. We have previously demonstrated that HDAC1 binds to the C-terminal region of pRb2/p130 (Stiegler et al., 1998) . Notably, also Ezh2/Eed-mediated gene repression requires HDAC1 activity (van der Vlag and Otte, 1999; Varambally et al., 2002) . Vlag et al. demonstrated that deacetylase activity is specifically associated with the Ezh2/Eed complex because HDAC proteins do not bind to other vertebrate PcG proteins (van der Vlag and Otte, 1999) . In this study, we show that Ezh2 interacts with pRb2/p130 both in vitro and in vivo. We demonstrate that the functional role of this binding is to interfere with the repressive activity of pRb2/p130 on cell cycle-promoting genes, underlying a new mechanism of inactivation of pRb2/p130 function depending on Ezh2 deregulation.
Results

Relationship between Ezh2 expression and malignant status in cell lines
Ezh2 is found to be deregulated in prostate cancer, breast cancer, Hodgkin's disease and B-cell nonHodgkin's lymphomas (Perou et al. , 2000; Raaphorst et al., 2000; van Kemenade et al., 2001; Visser et al., 2001; Varambally et al., 2002; Kleer et al., 2003; Rhodes et al., 2003) . We evaluated the expression of Ezh2 protein in normal and tumor cell lines of breast, prostate and lung origin. A representative panel in Figure 1 shows a higher expression of Ezh2 protein in all the tumor cell lines analyzed compared to the normal counterpart. It is worth noting that there was also a difference in Ezh2 expression between the normal and tumor breast cell lines originating from the same patient ( Figure 1 , HS578 bst and HS578 T). This, together with previous reports, suggests a correlation between Ezh2 expression and the transformed phenotype of mammalian cells.
Ezh2 expression is not cell cycle-dependent
It is not clear, however, if Ezh2 is upregulated as a consequence of increased proliferation occurring in tumor cell lines or whether the upregulation of Ezh2 causes an increase in their proliferation rate. The clear correlation between Ezh2 expression and the transformed phenotype of the human cell lines considered in Figure 1 made them a suitable system to address this issue. G 0 /G 1 growth-arrested cells, consequent to serum starvation, did not show changes in Ezh2 protein level (Figure 2a ) indicating that Ezh2 is not cell cycle-related. Flow cytometry analysis of serum-starved cell lines is shown in Figure 2b . The demonstration that Ezh2 is not cell cycle-related in the cell lines shown also in Figure 1 can better indicate that increased expression of Ezh2 in tumor cell lines depends on their malignant status. A similar result was recently published by Bracken et al (2003) . In their study, they observe that neither Ezh2 nor Eed are cell cycle-regulated proteins, although they Figure 1 Overexpressed Ezh2 levels in tumor cell lines. Immunoblots of breast, prostate and lung cell lines. Protein analysis of the five tumor cell lines presents higher Ezh2 expression compared to the corresponding normal cell lines. Whole-cell lysates were separated on 10% SDS-polyacrylamide gels and incubated with a monoclonal a-Ezh2 antibody. Hs 578Bst: normal mammary epithelium; Hs 578T: breast carcinoma (Hs 578Bst and Hs 578T originating from the same patient); MCF-12A: normal mammary epithelium; MCF-7: breast carcinoma; NPTX-1532: normal prostate epithelium; RWPE-1: normal prostate epithelium; C42: prostate carcinoma; C42B: prostate carcinoma; IMR-90: normal lung fibroblasts; NCI-H23: non-small-cell lung cancer Ezh2 interferes with cyclin A transcriptional repression T Tonini et al demonstrated that their protein level is strongly cell growth-regulated. These additional data strengthen our hypothesis indicating that Ezh2 upregulation depends on the malignant status of the cell lines rather than their proliferation rate.
Ezh2 and pRb2/p130 interact in vivo and in vitro
To understand the mechanism by which Ezh2 could lead to tumor progression, we analyzed its relationship with the Rb family member pRb2/p130, which is known to possess growth-suppressive properties. To determine if Ezh2 and pRb2/p130 exist as a complex in vivo, we carried out immunoprecipitation experiments using murine NIH/3T3 cells cotransfected with pRb2/p130 and Ezh2. Indeed, Ezh2 was immunoprecipitated using an anti-c-myc antibody, resulting in the co-immunoprecipitation of pRb2/p130 (Figure 3a) . Additionally, we could detect Ezh2 in pRb2/p130 immunoprecipitates (Figure 3b ), thus providing further evidence that Ezh2 and pRb2/p130 exist as a complex in vivo. We then performed an immunoprecipitation of the endogenous proteins (Figures 3c and d) . The results showed that antiserum that specifically immunoprecipitates Ezh2 (Figure 3c ) co-precipitated pRb2/p130 from the C42 prostate tumor cell line. Furthermore, in reciprocal experiments, Ezh2 was retained in pRb2/p130 immunoprecipitates ( Figure 3d ). These retentions were specific as they were not observed with an irrelevant antibody such as control normal rabbit serum (Figure 3c and d, (Total lysate) were IP with a monoclonal anti-myc antibody or a control normal mouse serum (NMS) and pRb2/p130 was detected by immunoblot analysis. Immunoprecipitation of Ezh2 was confirmed by immunoblot using anti-myc antibody. (b) To confirm the in vivo interaction, pRb2/p130 was IP from the transfected NIH/3T3 cells with a monoclonal anti-pRb2/p130 antibody (Transduction Laboratories, Lexington, KY, USA) and Ezh2 was detected by immunoblot analysis. Immunoprecipitation of pRb2/p130 was confirmed by immunoblot using anti-pRb2/p130 antibody. (c) Endogenous pRb2/p130 and Ezh2 coprecipitate from C42 cell extracts. Whole-cell extracts (Total lysate) were IP with anti-Ezh2 polyclonal antibody (a kind gift from Dr A Ullrich) or a control normal rabbit serum (NRS), and pRb2/p130 was detected by immunoblot analysis. Immunoprecipitation of Ezh2 was confirmed by immunoblot using anti-Ezh2 monoclonal antibody. (d) A polyclonal anti-pRb2/p130 (Santa Cruz Biotechnology, Inc., CA, USA) was used to immunoprecipitate the endogenous pRb2/p130, and Ezh2 was detected by immunoblot analysis. Immunoprecipitation of pRb2/p130 was confirmed by immunoblot using anti-pRb2/ p130 antibody. The co-immunoprecipitations were specific because pRb2/p130 and Ezh2 were not detected using as irrelevant antibodies an NMS (a and b) or an NRS (c and 3d) Ezh2 interferes with cyclin A transcriptional repression T Tonini et al NRS lanes). In summary, our results provide evidence for specific in vivo complex formation between pRb2/ p130 and Ezh2. We then determined which regions were important for the interaction between Ezh2 and pRb2/ p130. We performed in vitro binding assays of in vitrotranslated 35 S-labeled Ezh2 with GST-fusion proteins of the NH 2 -terminus, pocket domain and COOH-terminal region of pRb2/p130, or with GST alone as a control. We observed an interaction between Ezh2 and the COOH-terminus of pRb2/p130 (Figure 4 , lane 5), while no binding was observed with the NH 2 -terminus or the pocket domain (Figure 4 , lanes 3 and 4).
Ezh2 reverses pRb2/p130-HDAC1-mediated repression of the cyclin A promoter
We previously investigated the effect of HDAC1 on the transcriptional repression of cyclin A mediated by the E2F-4/pRb2/p130 complex (Stiegler et al., 1998) . The binding of HDAC1 to pRb2/p130 increases its ability to inhibit transcription of the E2F-dependent cyclin A promoter in vivo. In the present study, we found that Ezh2 was able to interfere with this repression, as shown in Figure 5 . Transfection of pRb2/p130 caused a moderate repression of the cyclin A promoter, probably due to the presence of endogenous HDAC1 ( Figure 5 , lane 2). In accordance with our previous results (Stiegler et al., 1998) , the repression was greatly increased when HDAC1 was cotransfected with pRb2/p130 ( Figure 5 , lane 3). This cooperative effect of HDAC1 and pRb2/ p130 on transcriptional repression was decreased when Ezh2 was also cotransfected ( Figure 5 , lanes 4 and 5), suggesting that Ezh2 abrogates the ability of pRb2/p130 to cause transcriptional repression of cyclin A, and this is likely due to a competition of Ezh2 for HDAC1 activity. Consistently with these data, it has been demonstrated that siRNA-mediated Ezh2 knockdown significantly reduces cyclin A mRNA levels (Bracken et al., 2003) . Conversely, ectopic expression of Ezh2 alone does not influence cyclin A expression (Varambally et al., 2002) . Ezh2 interferes mostly with the activity of pRb2/p130 since immunoblot analysis performed on cell lines transfected with Ezh2 revealed an unchanged pRb2/p130 protein level (data not shown).
pRb2/p130 association with HDAC1 activity is lost by ectopic expression of Ezh2
Consistently with previous data (Ferreira et al.,. 1998 ; Magnaghi-Jaulin et al., 1998), we were able to detect HDAC1 activity in pRb2/p130 immunoprecipitates from NIH3T3 cells ( Figure 6 , lane 2). Given that both Ezh2 and HDAC1 bind to the C-terminal region of pRb2/p130, we investigated whether ectopic expression of Ezh2 could cause the displacement of HDAC1. Indeed, ectopic expression of Ezh2 decreased the deacetylase activity associated with pRb2/p130 by 45% (Figure 6 , lane 4), indicating that Ezh2 could compete with HDAC1 for occupancy of the pRb2/p130 C-terminus. Control normal mouse serum (NMS) did not retain HDAC1 activity (Figure 6, lanes 1 and 3) .
Ezh2 displaces the pRb2/p130-HDAC1 complex associated to E2F target sequence on the cyclin A promoter
To investigate whether Ezh2 can decrease the level of the pRb2/p130-HDAC1 complex at the E2F-binding sites of the cyclin A promoter, a series of EMSAs were performed using an oligonucleotide probe representing the consensus E2F-binding sites from the human cyclin A promoter. NIH/3T3 cells were transfected with pCDNA3, pRb2/p130, pRb2/p130 and HDAC1, or pRb2/p130 together with HDAC1 and Ezh2 mammalian expression plasmids. In order to analyse binding of cellular proteins to these motifs, we performed this assay using double-stranded oligonucleotides (20-oligomer) containing two E2F consensus binding sites in the region of the cyclin A promoter spanning À90/ þ 1. As shown in Figure 7 , a specific complex was detected by EMSA. The complex formed when pRb2/p130 was overexpressed (lane 2) and was significantly stronger when also HDAC1 was cotransfected (lane 3). Interestingly, a striking decrease in the complex formation was noted when also Ezh2 was cotransfected (lane 4), indicating its involvement in disrupting pRb2/p130-HDAC1 occupancy on the cyclin A promoter. Monoclonal antibodies raised against pRb2/p130 supershifted the complex, causing the disappearance of the band from the gel (lane 5). The supershift indicates that the complex contains the pRb2/p130 protein. Similarly, antibodies raised against HDAC1 abolished the complex, indicating that it contains the HDAC1 protein (lane 6). On the contrary, control normal mouse serum did not alter the binding pattern (lane 7). Specific mutations of the oligonucleotide cycAwt resulted in the mutant oligonucleotide (cycAmut), with an abolished ability to bind to E2F (lane 8). To distinguish nonspecific binding to the cyclin A promoter, competition reactions were performed by adding 100-fold excess of nonradiolabeled cycAwt (lane 9) to the binding reaction mixture before adding the labeled probe.
Discussion
PcG proteins are a group of gene regulatory factors that are best known to regulate embryonic development as inhibitors of homeobox gene expression. So far, many investigators have demonstrated that interference with the expression levels of almost any vertebrate PcG protein leads to cellular transformation (Haupt et al., 1991; van Lohuizen et al., 1991; Cohen et al., 1996; Jacobs et al., 1999a) , but little is known about their mechanism in malignant transformation and how the PcG complexes are associated with their target genes. Recent evidence supports the involvement of Ezh2, a member of the PcG proteins, in progression of prostate, breast and lung cancer as well as lymphomas (Perou et al., 2000; Raaphorst et al., 2000; van Kemenade et al., 2001; Varambally et al., 2002; Kleer et al., 2003; Rhodes et al., 2003) . Consistently with previous results, we detected an increase in Ezh2 protein levels in different tumor cell lines compared to the normal counterpart, suggesting that its upregulation could be involved in Figure 6 Ezh2 decreases the amount of deacetylase activity associated with pRb2/p130. NIH/3T3 whole-cell extracts were immunoprecipitated (IP) by anti-pRb2/p130 monoclonal antibody or normal mouse serum (NMS) and immunoprecipitates were assayed for deacetylase activity. Immunoprecipitation of pRb2/ p130 retains deacetylase activity (lane 2). Ectopic expression of Ezh2 leads to a decrease in deacetylase activity associated with pRb2/p130 (lane 4). We used an NMS as an irrelevant antibody. NMS does not retain HDAC1 activity (lanes 1 and 3) , indicating that the retention of deacetylase activity is specific to pRb2/p130 The results presented here provide evidence of an interaction between Ezh2 and pRb2/p130, a member of the Rb family. We investigated the function of this interaction by demonstrating that this complex has a role in regulating cell cycle progression. Functional inactivation of pRb2/p130 has already been associated with disease progression and with high tumor grade (Claudio et al., 2002b) . It exhibits its growth-suppressive properties by silencing specific genes that are required for cell cycle progression. In order to do that, pRb2/p130 recruits HDAC1 to E2F-dependent promoters contributing to a transcriptionally repressed state of the chromatin. Likewise, Ezh2 controls gene repression through the recruitment of HDAC1. Both Ezh2 and pRb2/p130 repress gene expression by recruiting HDAC1. pRb2/p130 requires HDAC1 activity in order to exert its cell growth suppressive properties and, conversely, Ezh2 needs the activity of HDAC1 to promote cell cycle progression. For these reasons, the implications of HDAC1 in cell cycle advancement seem to be strictly correlated with its molecular partners. The inhibition of the HDAC1 activity associated with either pRb2/p130 or Ezh2 is likely to influence the cell cycle in opposite directions. We demonstrated that Ezh2 is able to interfere with the transcriptional repression of cyclin A mediated by the E2F4-pRb2/p130 complex, which is known to be dependent on HDAC1 activity (Stiegler et al., 1998) . This suggests that Ezh2 could compete with pRb2/p130 for HDAC1 activity. The significance of this observation is consistent with the known biological role of cyclin A. Its function is crucial for cell cycle advancement since it mediates entry into S phase and transition from G 2 to M phase of the cell cycle (Guadagno and Newport, 1996) . Furthermore, using HDAC1 assays, we demonstrated that ectopic expression of Ezh2 decreases the amount of deacetylase activity associated with pRb2/p130 by 45%, suggesting that the in vivo interaction between HDAC1 and pRb2/p130 could be targeted by Ezh2 through its binding to pRb2/p130. Finally, results from electromobility shift assays show that overexpression of Ezh2 abolishes the occupancy of the pRb2/p130-HDAC1 complex on the cyclin A promoter. These observations support the idea that Ezh2 competes for HDAC1 activity, suggesting for the first time a molecular mechanism that underlies malignant transformation due to an upregulation of Ezh2 expression. Since several investigators pointed out that interference with HDAC1's ability to interact with pRb2/p130 could lead to progression through the commitment point and ultimately to cell transformation and oncogenesis, we suggest that the Ezh2 overexpression found in tumors is crucial for inducing cell cycle progression. Interestingly, several observations indicate the role of pRb2/p130 in differentiation (Raschella et al., 1998; Galderisi et al., 2001; Raschella et al., 2001) . Furthermore, the loss of pRb2/p130 expression has been found to be directly correlated with a lesser cellular differentiation (Bellan et al., 2002) , suggesting a role of pRb2/p130 in triggering differentiation-specific genes. Similarly, the role of Ezh2 in differentiation has been extensively studied, suggesting an intriguing correlation with pRb2/p130 functional loss by Ezh2 overexpression and differentiation. pRb2/ p130 plays an important role in cell cycle control and its functional loss, whether by mutations found in tumors, by viral-transforming proteins or, as proposed here, by Ezh2 competition for the HDAC1 activity consequently leading to the abolishment of pRb2/p130-HDAC1 binding to the cyclin A promoter, not only results in the loss of active repression but, more importantly, could contribute to malignant transformation.
Materials and methods
Cell culture and transient transfections
The NIH/3T3 mouse embryo fibroblasts, the MCF-7 breast carcinoma cell line, the MCF-12A mammary epithelial cell line, the IMR-90 normal lung fibroblasts, the NCI-H23 nonsmall-cell lung cancer cell line and the RWPE-1 normal prostate epithelial cell line, were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and were cultured according to the manufacturer's protocols. The C42 and C42B prostate tumor cell lines were purchased from UroCor (Oklahoma City, OK, USA). The Hs 578Bst normal mammary epithelial cell line and the Hs 578T breast carcinoma cell line originated from the same patient and were kindly donated by Dr GP Tuszynski, as was the NPTX-1532 normal prostate epithelial cell line. The Hs 578Bst and Hs 578T cell lines were grown according to the manufacturer's protocols (ATCC) and the C42, C42B and NPTX-1532 cell lines were grown in DMEM containing 10% fetal calf serum (FCS) in a 5% CO 2 atmosphere at 371C. NIH/3T3 cells were transfected in 100-mm culture dishes using a Polyfect/DNA mixture according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). Cells were incubated at 371C for 48 h after transfection and then collected for further analysis. Luciferase assays were performed according to the Promega protocol and b-galactosidase was assayed as previously described (Stiegler et al., 1998) .
Plasmids
The pGEX-2T plasmids containing the N-terminus, the pocket and the C-terminal region of pRb2/p130 have been previously described (De Luca et al., 1997b) . The myc-Tag Ezh2 was a generous gift of AM Chinnaiyan. pSV-b-galactosidase control vector was obtained from Promega (Promega, Madison, WI, USA). The cyclin A promoter fragment-luciferase construct, the myc-Tag HDAC and the pRb2/p130 have been previously described (Stiegler et al., 1998) .
Immunoblotting and immunoprecipitation
Cells were lysed in lysis buffer (50 mM Tris-Cl, pH 7.4,. 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM Na 3 VO 4 , 1 mM PMSF, 10 mg/ml Leupeptin). An equal amount of 50 mg of protein extract was loaded into 10% SDS polyacrylamide gels (SDS-PAGE) and then immunoblotted using a monoclonal anti-Ezh2 antibody (a kind gift from Dr A Otte). Anti-Hsp72/73 monoclonal antibody was purchased from Oncogene Science, Inc. (Cambridge, MA, USA).
Immunoprecipitations were performed as previously described (De Luca et al., 1997b) . Briefly, equal amounts of whole-cell extracts were IP overnight with 2 mg of the indicated antibodies and subsequently incubated with G-Sepharose (Pierce 
In vitro binding assay
An amount of 1 mg of plasmid encoding wild-type Ezh2 was in vitro-translated with T7 RNA polymerase using a translation kit (Promega, Madison, WI, USA). GST-fusion protein preparation was performed as previously described (De Luca et al., 1997b) . Briefly, XL1-Blue bacteria carrying pGEX-2T vectors were grown to midlog phase then induced to express protein by the addition of isopropyl-1-thio-b-D-galactopyranoside to the media. Bacteria were then pelleted and resuspended in NENT buffer (20 mM Tris, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40). Cell suspensions were sonicated and pelleted. The supernatant was incubated with glutathioneagarose (Amersham Pharmacia Biotech, Inc.) overnight at 4 1C. The agarose was pelleted and washed three times in NENT buffer. Fusion proteins were run in a 10% polyacrylamide gel and detected by Coomassie blue staining. Aliquots of the reaction mixture were added to glutathione/Sepharose beads coupled with 2 mg of GST chimerized with either the Nterminal region of pRb2/p130, the pocket domain or the COOH-terminal region. Incubation was carried out in NENT buffer (20 mM Tris-Cl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 % NP-40, 1 mM PMSF and 10 mg/ml leupeptin) for 60 min at 41C with gentle rocking. Beads were washed three times in NENT buffer, and electrophoresis was performed on a 10% acrylamide SDS-PAGE. Gels were dried and exposed at À701C using Kodak Biomax MS films.
Deacetylase assay
Immunoprecipitates from 2 mg of total cell lysate were incubated with 2 ml of an acetylated peptide corresponding to amino acids 2-24 of Histone H4 (20 000 c.p.m.) for 6 h at 371C and deacetylase activity was determined according to the manufacturer's instructions (Upstate Cell Signaling Solutions, NY, USA).
Electromobility shift assay
Nuclear extracts were prepared as described previously (Andrews and Faller, 1991) . Briefly, washed cell pellets (5 Â 10 6 cells) were resuspended in 0.5 ml of cold hypotonic buffer (10 mM HEPES-KOH, pH 7.9; 10 mM KCl; 1.5 mM MgCl 2 ; 0.5 mM dithiothreitol; 0.2 mM phenylmethylsulfonyl fluoride; 50 mM sodium fluoride; 10 mg of leupeptin/ml; 10 mg of aprotinin/ml) and allowed to swell on ice for 10 min. The cells were collected in an Eppendorf microcentrifuge and the pellet was resuspended in 25-50 ml of cold lysis buffer (20 mM HEPES-KOH, pH 7.9; 25% glycerol; 420 mM NaCl; 1.5 mM MgCl 2 ; 0.2 mM EDTA; 0.5 mM dithiothreitol; 0.2 mM phenylmethylsulfonyl fluoride; 50 mM sodium fluoride; 10 mg of leupeptin/ml; 10 mg of aprotinin/ml). After incubation on ice for 20 min, cellular debris was removed by full-speed centrifugation in an Eppendorf microcentrifuge (2 min, 41C), and supernatants (nuclear extracts) were quick-frozen and stored as aliquots at À801C. Proteins were quantified by the Bradford dye-binding procedure (Bio-Rad). Single-stranded oligonucleotides (20-oligomer) containing two E2F consensus binding sites in the region of the cyclin A promoter spanning À90/ þ 1 were 5 0 end labeled with [g-32P]ATP (3000 Ci/mmol) and T4polynucleotide kinase (Life Technologies). The two E2F consensus binding sites (5 0 -TTT(C/G)(C/G)CGC-3 0 ) were mutated to construct the mutated oligonucleotide (20-oligomer) used for cold competition assay. Sequences of the oligonucleotides will be provided upon request. Oligonucleotides were annealed at room temperature for 15 min and the probe was purified by using a Microspin G-50 column (Amersham Pharmacia Biotech, Inc.). Specific activities were typically 5 Â 10 8 -10 Â 10 8 c.p.m./mg. For electromobility shift assay analyses, 5 mg of nuclear extracts were incubated with 1 mg of poly(dI-dC)-poly(dI-dC) (Pharmacia) in binding buffer (10 mM Tris-HCl, pH 7.5; 50 mM NaCl; 0.5 mM dithiothreitol; 0.05% NP-40; 10% glycerol; 0.2 mM phenylmethylsulfonyl fluoride; 50 mM sodium fluoride; 10 mg of leupeptin/ml; 10 mg of aprotinin/ml) in a final volume of 20 ml . After incubation for 10 min at room temperature, a DNA probe (6 Â 10 4 c.p.m.) was added to the mixture, followed by incubation for 15 min at room temperature. For competition experiments, a 100-fold molar excess of unlabeled competitor DNA was added to the reaction mixture prior to addition of the radioactive probe. For the supershift experiments, nuclear extracts in 20 ml of binding buffer were preincubated (1 h in ice) with 1 mg of a monoclonal antibody against pRb2/p130 (Signal Transduction Laboratories, Lexington, KY, USA), monoclonal antibody against HDAC-1 (Upstate Cell Signaling Solutions, NY, USA), or a control NMR prior to addition of the radioactive probe. Protein-DNA complexes were separated on a 5% polyacrylamide gel in 22.5 mM Tris-22.5 mM boric acid-62.5 mM EDTA (pH 8) at 160 V for 3 h at 41C. The gels were dried and analyzed by autoradiography.
